Genomics
Detects sequence variation associated disease signals.
aitios® Platform - Overview
AI-powered liquid biopsy.
We are building the first tissue-resolved liquid biopsy platform powered by multi-modal sequencing and artificial intelligence.
Technological Principles
Actionable tissue-resolved readout from cfDNA.
Our patented aitios® platform combines advanced DNA sequencing, multi-modal AI, and scalable cloud analytics to identify tissue- and cell-type specific disease signals from a standard blood draw.
Fragmentomics & Methylation
Interprets regulatory and cell-type specific methylation and fragmentomic patterns.
AI-Powered Interpretation
Combines genomics, fragmentomics, and methylation for tissue-specific resolution of health and disease signals.
Biological Principles
Resolving tissue- and cell-type-specific biology from cfDNA.
Cells across the body continuously release DNA into the bloodstream. These cell-free DNA fragments carry molecular signatures that reflect their tissue of origin and underlying biological state. We decode these signals by combining multiple layers of information from native cfDNA.
Tissue-Specific Methylation
DNA methylation patterns are highly cell-type specific and regulate gene expression programs. By analyzing these patterns, we identify the tissue of origin and functional state of cfDNA signals.
Tissue-Specific Fragmentomics
cfDNA fragmentation reflects chromatin structure and nucleosomal organization. These patterns provide an additional, independent layer of cell-type and regulatory information.
Workflow
